Primary treatment of AL amyloidosis is to target the plasma cell clone which produces the immunoglobulin light chain precursor of amyloid fibrils. A number of chemotherapeutic regimens have been used and all have shown varying response in individual patients. Most recently, bortezomib (Velcade) has been used with consistent success as not only a primary but also a secondary line therapy for patients with either multiple-myeloma or AL amyloidosis. Here, we report the experience with use of bortezomib for AL amyloidosis at Indiana University Medical Center.
ASJC Scopus subject areas
- Internal Medicine